Heart Test Laboratories Statistics
Share Statistics
Heart Test Laboratories has 913.82K shares outstanding. The number of shares has increased by -91.64% in one year.
| Shares Outstanding | 913.82K |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 39.31% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 816.63K |
| Failed to Deliver (FTD) Shares | 1.93K |
| FTD / Avg. Volume | 0.57% |
Short Selling Information
The latest short interest is 23.08K, so 2.53% of the outstanding shares have been sold short.
| Short Interest | 23.08K |
| Short % of Shares Out | 2.53% |
| Short % of Float | 2.83% |
| Short Ratio (days to cover) | 0.49 |
Valuation Ratios
The PE ratio is -0.49 and the forward PE ratio is -0.46.
| PE Ratio | -0.49 |
| Forward PE | -0.46 |
| PS Ratio | 175.12 |
| Forward PS | 68.9 |
| PB Ratio | 0.45 |
| P/FCF Ratio | -0.53 |
| PEG Ratio | n/a |
Enterprise Valuation
Heart Test Laboratories Inc. has an Enterprise Value (EV) of 6.62M.
| EV / Earnings | -1 |
| EV / Sales | 356.11 |
| EV / EBITDA | -1.08 |
| EV / EBIT | -1.05 |
| EV / FCF | -1.07 |
Financial Position
The company has a current ratio of 4.2, with a Debt / Equity ratio of 0.07.
| Current Ratio | 4.2 |
| Quick Ratio | 3.84 |
| Debt / Equity | 0.07 |
| Total Debt / Capitalization | 6.4 |
| Cash Flow / Debt | -12.14 |
| Interest Coverage | -17.81 |
Financial Efficiency
Return on equity (ROE) is -0.9% and return on capital (ROIC) is -75.49%.
| Return on Equity (ROE) | -0.9% |
| Return on Assets (ROA) | -0.7% |
| Return on Capital (ROIC) | -75.49% |
| Revenue Per Employee | 1.24K |
| Profits Per Employee | -440.35K |
| Employee Count | 15 |
| Asset Turnover | 0 |
| Inventory Turnover | 0.01 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -78.71% in the last 52 weeks. The beta is 3.29, so Heart Test Laboratories 's price volatility has been higher than the market average.
| Beta | 3.29 |
| 52-Week Price Change | -78.71% |
| 50-Day Moving Average | 3.3 |
| 200-Day Moving Average | 5.85 |
| Relative Strength Index (RSI) | 66.02 |
| Average Volume (20 Days) | 340.54K |
Income Statement
In the last 12 months, Heart Test Laboratories had revenue of $18.60K and earned -$6.61M in profits. Earnings per share was $-18.74.
| Revenue | 18.60K |
| Gross Profit | 12.52K |
| Operating Income | -6.31M |
| Net Income | -6.61M |
| EBITDA | -6.16M |
| EBIT | -6.31M |
| Earnings Per Share (EPS) | -18.74 |
Balance Sheet
The company has $5.81M in cash and $1.04M in debt, giving a net cash position of $4.77M.
| Cash & Cash Equivalents | 5.81M |
| Total Debt | 1.04M |
| Net Cash | 4.77M |
| Retained Earnings | -67.36M |
| Total Assets | 8.19M |
| Working Capital | 4.06M |
Cash Flow
In the last 12 months, operating cash flow was -$6.07M and capital expenditures -$125.27K, giving a free cash flow of -$6.20M.
| Operating Cash Flow | -6.07M |
| Capital Expenditures | -125.27K |
| Free Cash Flow | -6.20M |
| FCF Per Share | -17.57 |
Margins
Gross margin is 67.31%, with operating and profit margins of -33.90K% and -35.51K%.
| Gross Margin | 67.31% |
| Operating Margin | -33.90K% |
| Pretax Margin | -35.51K% |
| Profit Margin | -35.51K% |
| EBITDA Margin | -33.10K% |
| EBIT Margin | -33.90K% |
| FCF Margin | -33.31K% |
Dividends & Yields
HSCS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -497.08% |
| FCF Yield | -179.92% |
Analyst Forecast
The average price target for HSCS is $15, which is 297.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 297.9% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on May 17, 2024. It was a backward split with a ratio of 1:100.
| Last Split Date | May 17, 2024 |
| Split Type | backward |
| Split Ratio | 1:100 |
Scores
| Altman Z-Score | -13.1 |
| Piotroski F-Score | 2 |